), isolates of S. pneumoniae cultured by the LTHTR microbiology laboratory were examined by Etest to determine MICs of levofloxacin. Isolates from patients in whom there was a shift towards colonization with S. pneumoniae of reduced levofloxacin susceptibility were further characterized by serotyping, multilocus sequence typing (MLST) and sequencing of parC and gyrA genes.
Introduction
Levofloxacin is a broad-spectrum third-generation fluoroquinolone with greater activity against Streptococcus pneumoniae than the older fluoroquinolones, and, in 1999, Lancashire Teaching Hospitals NHS Foundation Trust (LTHTR) adopted it as firstline treatment of severe community-acquired pneumonia and hospital-acquired pneumonia as well as sepsis of unknown source, as recommended by hospital guidelines. As a result, quinolone use in our trust became more than double that of a similar large teaching hospital, 1 the defined daily dose (DDD)/ 100 bed days occupied, for levofloxacin and ciprofloxacin, averaging out at 8.4 and 7.4, respectively, in 2004.
Having had 5 years of extensive hospital use of levofloxacin, we aimed to investigate the impact that this was having on S. pneumoniae resistance rates. We also set out to identify any incidences of resistance development in individual patients, and to investigate whether or not this was due to de novo resistance development or replacement of susceptible strains by more resistant ones. Approval was obtained from the Cumbria and Lancashire B Research Ethics Committee before commencing (REC reference: 04/Q1301/17).
Methods
During the period September 2004-February 2007, all isolates of S. pneumoniae isolated in Lancashire Teaching Hospitals Microbiology Department, from any body site and any location (including the community), were eligible for inclusion in the study. Biomedical scientists were prompted to store isolates via the laboratory computer system. The isolates were stored in brain heart infusion broth with 20% glycerol at 2208C, and approximately every 3 months batches were subcultured on Columbia horse blood agar plates and then inoculated onto Isotest agar with 5% defibrinated horse blood and 20 mg/L NAD for susceptibility testing by Etest according to the manufacturer's instructions (AB Biodisk, Solna, Sweden). Strain NCTC 12977, for which the MIC is known, was used for quality control with each batch. All E-strips were read by the same investigator.
The isolates were then stored at 2708C on Protect microbank beads (Prolab Diagnostics) and, at the end of the study period, isolates from patients in whom there was a shift to infection or colonization with more resistant S. pneumoniae were subcultured and tested by VITEK 2 (bioMérieux) for susceptibility to other antimicrobial agents (card P533), and phenotypic and genotypic characterization was undertaken at the Respiratory and Systemic Infection Laboratory, Health Protection Agency-Centre for Infections, London, UK.
Clinical information on previous chronic respiratory conditions was obtained from microbiology request forms, the hospital electronic patient record and paper case notes.
Phenotypic and genetic characterization
Pure cultures referred to the Respiratory and Systemic Infection Laboratory were serotyped by slide agglutination using capsular antisera (Statens Serum Institute, Denmark). Multilocus sequence typing (MLST) was carried out as described previously. 2 Allele and sequence type (ST) assignment was performed using the Bionumerics pipeline. 3 Mutations in the quinolone resistance determining regions (QRDRs) of parC and gyrA were determined by sequence analysis. 4 QRDRs were amplified by PCR using M0363/M4271 primers for parC and VGA3/VG4 primers for gyrA. PCR primers were used for sequencing reactions. QRDR sequences were compared with reference sequences (GenBank accession numbers: parC, AJ005815; gyrA, Z67739). Sequences were aligned using the BioEdit (version 7.0.9.0) package.
Results
Of 1205 isolates of S. pneumoniae eligible for inclusion in the study between September 2004 and February 2007, 865 were actually captured, and, of these, 772 isolates were recoverable from storage for testing. The mean age of the 652 patients from whom isolates were recovered was 37.5 years (median 43.3 years); 47.7% were female. Four hundred and twelve (53.4%) recovered isolates came from hospitalized patients, and sputum was the most common site (48.9%), followed by eye (24.1%), ear (14.8%) and blood cultures (6.5%).
The MIC range, MIC 50 and MIC 90 of levofloxacin were 0.24 to .32 mg/L, 0.75 mg/L and 1.0 mg/L, respectively. When Etest MIC values were rounded to the nearest doubling dilution for comparison with BSAC breakpoints, only 12 (1.6%) isolates, from 10 patients, were regarded as resistant according to the BSAC breakpoint (.2 mg/L); 29 (3.8%) isolates had MIC values at the breakpoint (MIC¼2 mg/L). 5 Of the resistant isolates, one was isolated in 2004, nine were isolated in 2005 and two were isolated in 2006.
Fifty-five patients were identified from whom S. pneumoniae had been cultured more than once (1 day apart), the median span of time between first and last specimens being 63 days (range 1 -695 days). Thirty-two of these patients were .16 years old (all of whom had S. pneumoniae isolated from sputum) and 22 of these adult patients had samples sent from within the hospital. We failed to identify any patients in whom there was a shift towards colonization with isolates of Orr et al.
S. pneumoniae with greater susceptibility to levofloxacin, but we identified six patients in whom there was a shift towards isolates with reduced susceptibility (see Table 1 ). One was a child (almost 12 months old), from whom the isolates were cultured from ear swabs collected in the community, and the other five were adults (mean age 68.8 years), four of whom had samples collected from within the hospital. All five adults had chronic respiratory conditions (chronic obstructive pulmonary disease and/or bronchiectasis, or emphysema). Of these six patients, five had acquired genetically distant pneumococcal clones from the original sample, suggesting distinct pneumococcal episodes, and one of these patients (patient D) had two distinct pneumococci identified within a 1 day interval (day 1, ST408/11A; day 2, ST65/6A), introducing the possibility of co-colonization by both strains, with only one being selected during primary plating/sub-plating. We identified one patient (patient A) in whom, over a 4 day interval, the MIC for the isolates increased from 1.5 to 32 mg/L, yet both isolates belonged to the same pneumococcal clone (ST311 serotype 23F).
Sequence analyses of parC and gyrA QRDRs in isolates from patient A demonstrated a probable de novo second-step mutation in the gyrA gene (Ser81Phe), which, in addition to a pre-existing first-step parC mutation (Ser79Phe), conferred resistance to levofloxacin. The same level of resistance was observed in the second isolate of patient B (ST199, serotype 15B). This isolate was also carrying the double mutation, gyrA (Ser81Phe) and parC (Ser97Phe).
Discussion
Despite 5 years of widespread hospital use of levofloxacin, only 1.6% of the isolates we examined in this study were resistant according to the BSAC breakpoint, and we found no evidence of a trend towards increased resistance over time. This is perhaps unsurprising if you consider that most patients with pneumococcal infections acquire them in the community, and therefore community use of quinolones, which is tightly controlled in our region (as in other regions of the UK), is probably a more important driver of resistance than hospital use. However, when we started this study, we expected to detect more de novo resistance development than was subsequently observed.
There have been multiple reports in the past of resistance development in patients treated with levofloxacin, 6, 7 and studies have shown that isolates, susceptible according to nationally accepted breakpoints, can carry first-step parC mutations, 8 which make resistance development on treatment more likely. 9 Yet, in the 2.5 years of this study, we detected only one convincing case of de novo second-step mutation leading to high-level levofloxacin resistance, despite the fact that we managed to capture repeat S. pneumoniae isolates from 32 adult patients. What initially seemed to be evidence of de novo resistance development was generally explained by strain replacement, or possibly by initial dual ST/serotype carriage, with the less susceptible sub-population being preferentially selected by antibiotic therapy. This suggests that person-to-person spread of resistant strains may contribute more to the prevalence of resistance than new mutations.
The relative infrequency of de novo resistance development that we observed may be partly explained by emerging evidence that some parC and gyrA first-step mutations, causing reduced levofloxacin susceptibility, also impose a fitness cost to S. pneumoniae strains. 10 This may lead to a smaller pool of first-step mutants available to subsequently develop resistance. It may also be partly explained by the hospital guideline's recommendation, throughout the study period, that intravenous benzylpenicillin be administered in addition to levofloxacin for the treatment of severe community-acquired pneumonia. However, as is demonstrated by the case of patient A, this recommendation was poorly adhered to.
Although observed infrequently, the case of patient A demonstrates that levofloxacin resistance can arise de novo in S. pneumoniae strains, particularly when a pre-existing first-step mutation is present. The first-step parC mutation (Ser79Phe) present in patient A's strain has been reported commonly in the literature, and was present in 47/115 S. pneumoniae strains with levofloxacin MICs 2 mg/L isolated in a Canadian study (the most common parC substitution detected). 7 The main weakness of studies based on laboratory samples is that they represent only a tiny proportion of the overall burden of disease. For most patients with S. pneumoniae infection, the organism is never cultured and resistance development can therefore be difficult to detect. The fact that we were able to detect even one case of mutation leading to levofloxacin resistance may be significant in itself.
